What question did this study set out to answer?

The review aims to analyze the use of immune checkpoint inhibitors in managing various urological cancers.

January 16, 2026Journal of the Association of Southern Urologists.0 citationsOpen Access

Immune Checkpoint Inhibitors in Urology

RPR. Vishnu PrakashGovernment Medical College AVA. V. VenugopalanGovernment Medical College SPSubeesh ParolGovernment Medical College

Key Points

The review aims to analyze the use of immune checkpoint inhibitors in managing various urological cancers.
Review of current literature on immune checkpoint inhibitors in urology
Examination of recent clinical trials regarding their efficacy
Analysis of treatment protocols and strategies employed
Immune checkpoint inhibitors are widely used in renal cell carcinoma treatment
Their application in bladder and prostate carcinoma is expanding
Recent trials show promising outcomes for patients with urological cancers

Abstract

Abstract Immune checkpoint inhibitors (ICIs) represent the next leap in the management of urological malignancies. In urology, ICIs are already used extensively in renal cell carcinoma and to extent in bladder carcinoma and prostate carcinoma. In this review article, we will be looking into ICIs’ use in various urological malignancies, the latest trials, and protocols.

问 AI

Bookmark

View Full Paper